IPP Bureau
Bridgewest Group launches new sterile injectable CDMO NovaCina
By IPP Bureau - April 06, 2023
Microbion gets US patent for the use of inhaled pravibismane for pulmonary infections
By IPP Bureau - April 06, 2023
Extends patent protection for Microbion's proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039
Lonza and ABL Bio collaborate on development and manufacture of new bispecific antibody product
By IPP Bureau - April 06, 2023
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
India showcases achievements in health sector in run up to 2nd G20 Health Working Group Meeting
By IPP Bureau - April 05, 2023
Successes under Ayushman Bharat Digital Health Mission and Pradhan Mantri National Dialysis Programme highlighted
SK Capital completes acquisition of Apotex
By IPP Bureau - April 05, 2023
Philips and Northwell Health partner to standardize patient monitoring across the enterprise
By IPP Bureau - April 05, 2023
New York State’s largest health system adopts Philips patient monitoring platform to drive integration and innovation for a better patient and staff experience and improved outcomes
LogiPharma launches Asian focused summit, coming to Singapore in June 2023
By IPP Bureau - April 05, 2023
The summit encompasses multiple verticals, spanning from pharmaceuticals, biotech, life sciences, and the Healthcare sector to ensure an unbiased and comprehensive view on the future of the function.
Dozee Raises $6 million to bolster its ambition of ‘HarBedDozeeBed’
By IPP Bureau - April 05, 2023
Dozee plans to further tap over 2,000 hospitals in more than 100 districts
Israeli researchers develop an effective drug to prevent muscle diseases
By IPP Bureau - April 05, 2023
The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.
FDA approves Merck’s Keytruda in combination with Padcev for treatment of metastatic urothelial cancer
By IPP Bureau - April 04, 2023
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
Biocon awarded Silver Medal by EcoVadis for sustainability accomplishments
By IPP Bureau - April 04, 2023
For the year 2022, Biocon bettered its score in all the four EcoVadis themes – Environment (70), Labor & Human Rights (70), Ethics (60), and Sustainable Procurement (60)
Top management changes at IOL Chemicals and Pharmaceuticals
By IPP Bureau - April 04, 2023
Vikas Vij has been appointed as Chief Executive Officer (CEO) of the company
Antibody-drug conjugates gain traction in China oncology market, says GlobalData
By IPP Bureau - April 04, 2023
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
TSCS team met All India Imam Organization Chief to discuss on thalassemia eradication in India
By IPP Bureau - April 04, 2023
Chief Imam of All India Imam Organization, Dr. Imam Umer Ahmed Ilyas, evinces keen interest in the eradication of Thalassemia & Sickle Cell Disease
CBC Group appoints Abbas Hussain as Operating Partner
By IPP Bureau - April 03, 2023
Abbas will closely partner with CBC's business teams to identify, assess, and pursue investment opportunities and strategic acquisitions
